Karuna Therapeutics, Inc.
(NASDAQ : KRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.45%166.930.7%$1253.55m
LLYEli Lilly & Co. 0.18%311.431.1%$814.08m
BMYBristol-Myers Squibb Co. -0.73%70.771.0%$778.85m
PFEPfizer Inc. -1.10%44.080.9%$769.71m
ABBVAbbVie, Inc. 0.04%143.061.9%$735.85m
MRKMerck & Co., Inc. -0.81%86.800.7%$691.58m
AZNAstraZeneca Plc -3.07%54.581.0%$397.16m
ALNYAlnylam Pharmaceuticals, Inc. -0.95%200.788.2%$207.03m
NVSNovartis AG -1.47%76.010.2%$201.13m
GBTGlobal Blood Therapeutics, Inc. 0.03%67.995.4%$199.71m
GSKGSK Plc -2.13%29.370.3%$192.16m
NVONovo Nordisk A/S -0.40%97.920.1%$170.11m
HZNPHorizon Therapeutics Plc 0.54%62.975.4%$156.21m
SGENSeagen Inc. -0.96%139.205.7%$152.48m
SRPTSarepta Therapeutics, Inc. -2.42%108.1912.4%$128.76m

Company Profile

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.